Savara (SVRA) Research Hub

Savara (SVRA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 4.52 USD (+7.11%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -10.09, market cap 1.16B. This hub links to the full technical, earnings and options research available for SVRA.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close4.52 USD (+7.11%)
52-week range4.13 USD – 6.48 USD
Trend regimeRange
14-day RSI46.7 (Neutral)
Trailing P/E-10.09
Market cap1.16B
Dividend yield0.00%
Next earnings2026-08-12

Available research for SVRA

Earnings

SVRA earnings date and last-quarter result: next report 2026-08-12, last quarter miss, P/E -10.09. Updated 2026-07-23.

Options: Covered Call

Covered Call on SVRA: how it works, illustrative setup around the real 4.52 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on SVRA: how it works, illustrative setup around the real 4.52 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on SVRA: how it works, illustrative setup around the real 4.52 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

SVRA technical analysis: range, last 4.52 USD, RSI 46.7, 52w range 4.13 USD–6.48 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is SVRA in?

Savara (SVRA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is SVRA in an uptrend or downtrend?

As of 2026-10-26, SVRA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is SVRA's trailing P/E ratio?

SVRA's trailing P/E is -10.09, with a market cap of 1.16B. See the earnings research page for full valuation detail.

When does SVRA next report earnings?

SVRA is next scheduled to report earnings on 2026-08-12.